We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+32.58%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$476M
Cap. Flow
+$118M
Cap. Flow %
5.96%
Top 10 Hldgs %
48.1%
Holding
113
New
18
Increased
27
Reduced
34
Closed
25

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$62.7M
2
ELV icon
Elevance Health
ELV
+$59M
3
TGTX icon
TG Therapeutics
TGTX
+$52.7M
4
TWST icon
Twist Bioscience
TWST
+$45.8M
5
NVCR icon
NovoCure
NVCR
+$36.6M

Top Sells

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$73.4M
2
STAA icon
STAAR Surgical
STAA
+$59.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$37.3M
4
GRFS
Grifois
GRFS
+$32.5M
5
URGN icon
UroGen Pharma
URGN
+$27M

Sector Composition

Rank Sector Weight
1 Healthcare 94.2%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
76
MannKind Corp
MNKD
$1.31B
$1.61M 0.08%
+300,000
New +$1.32M
IMUX icon
77
Immunic
IMUX
$211M
$1.39M 0.07%
158,001
-571,300
-78% -$5.04M
ADVM
78
DELISTED
Adverum Biotechnologies
ADVM
$1.3M 0.07%
287,246
– –
LQDA icon
79
Liquidia Corp
LQDA
$7.9B
$1.14M 0.06%
+50,000
New +$1.08M
EPIX
80
DELISTED
ESSA Pharma
EPIX
$833K 0.04%
4,362,026
+2,100,000
+93% +$2.52M
MYO icon
81
Myomo
MYO
$51.5M
$628K 0.03%
704,275
– –
MREO
82
Mereo BioPharma
MREO
$47.8M
$617K 0.03%
299,711
-300,000
-50% -$553K
TECX
83
Tectonic Therapeutic
TECX
$584M
$392K 0.02%
25,000
-51,841
-67% -$1.07M
INSM icon
84
Insmed
INSM
$28.3B
$367K 0.02%
2,550
-70,222
-96% -$8.6M
SEPN
85
Septerna Inc
SEPN
$1.74B
$343K 0.02%
18,260
-57,196
-76% -$751K
KOD icon
86
Kodiak Sciences
KOD
$2.85B
$322K 0.02%
+19,644
New +$169K
TRVI icon
87
Trevi Therapeutics
TRVI
$2.59B
$229K 0.01%
25,000
-675,000
-96% -$5.06M
DCTH icon
88
Delcath Systems
DCTH
$535M
$108K 0.01%
10,000
-15,000
-60% -$167K
ABVX
89
Abivax
ABVX
$11.4B
– –
-125,000
Closed -$956K
ADPT icon
90
Adaptive Biotechnologies
ADPT
$3.9B
– –
-10,000
Closed -$117K
ASND icon
91
Ascendis Pharma A/S
ASND
$16.6B
– –
-85,000
Closed -$14.7M
AXSM icon
92
Axsome Therapeutics
AXSM
$10.8B
– –
-2,000
Closed -$209K
BCYC
93
Bicycle Therapeutics
BCYC
$288M
– –
-100,000
Closed -$695K
CTMX icon
94
CytomX Therapeutics
CTMX
$734M
– –
-1,304,300
Closed -$2.96M
DNLI icon
95
Denali Therapeutics
DNLI
$3.86B
– –
-182,110
Closed -$2.55M
ENOV icon
96
Enovis
ENOV
$1.46B
– –
-315,000
Closed -$9.88M
EWTX icon
97
Edgewise Therapeutics
EWTX
$4.6B
– –
-76,493
Closed -$1M
HUM icon
98
Humana
HUM
$46.1B
– –
-79,600
Closed -$19.5M
IOBT
99
DELISTED
IO Biotech
IOBT
– –
-192,670
Closed -$268K
MRUS
100
DELISTED
Merus
MRUS
– –
-40,000
Closed -$2.1M
1 2 3
4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Soleus Capital Management held 113 positions worth $1.99B, up 32% from $1.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Soleus Capital Management deployed $118M of net new capital in Q3 2025, opening 18 new positions and adding to 27 existing holdings. Its largest new stake was Amicus Therapeutics: 4,690,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Celcuity, an estimated $73.4M trimmed.

  • Soleus Capital Management's largest Q3 2025 buy was Amicus Therapeutics: 4,690,000 shares worth $37M.
  • Soleus Capital Management added most to Inspire Medical Systems in Q3 2025, an estimated $62.7M increase.
  • Soleus Capital Management's biggest Q3 2025 reduction was Celcuity, cutting an estimated $73.4M.
  • Soleus Capital Management fully exited UnitedHealth in Q3 2025, selling an estimated $26.9M.
  • Soleus Capital Management's ten largest holdings make up 48% of its $1.99B portfolio in Q3 2025.
  • Soleus Capital Management opened 18 new positions and closed 25 in Q3 2025.
  • Soleus Capital Management's portfolio value rose 32% quarter-over-quarter to $1.99B.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.